Tai Chi for Patients With Essential Hypertension
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04267471 |
Recruitment Status :
Not yet recruiting
First Posted : February 12, 2020
Last Update Posted : February 24, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Behavioral: Tai Chi Behavioral: Walking | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 234 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Tai Chi for Patients With Essential Hypertension: Study Protocol of an Open-label Single-center Randomized Controlled Trial |
Estimated Study Start Date : | June 2020 |
Estimated Primary Completion Date : | September 2022 |
Estimated Study Completion Date : | December 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Tai Chi
3 sessions of Tai Chi per week for 12 weeks
|
Behavioral: Tai Chi
Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
Other Name: Tai Ji Quan |
Active Comparator: Walking
3 sessions of walking per week for 12 weeks
|
Behavioral: Walking
Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down. |
No Intervention: Waiting-list |
- average 24-h Systolic Blood Pressure (SBP) [ Time Frame: change from baseline to 12 weeks after intervention ]
- average SBP and average Diastolic Blood Pressure (DBP) [ Time Frame: baseline, after intervention(12 week), after follow-up(24 week) ]average SBP and average DBP during the daytime and night-time
- change of serum concentrations of Nitric Oxide [ Time Frame: baseline, after intervention(12 week) ]
- change of serum concentrations of endothelin [ Time Frame: baseline, after intervention(12 week) ]
- change of serum concentrations of thromboxane A2 [ Time Frame: baseline, after intervention(12 week) ]
- change of serum concentrations of vascular endothelial growth factor [ Time Frame: baseline, after intervention(12 week) ]
- blood pressure measured at home with an upper arm electronic sphygmomanometer [ Time Frame: baseline, after intervention(12 week), after follow-up(24 week) ]
- Medical Outcomes Study 36-Item Short Form [ Time Frame: baseline, after intervention(12 week) ]This scale contains eight dimensions (physical function, role physical, bodily pain, general health, vitality, social function, role emotional, mental health) and two summary components (physical and mental), with score from 0 to 100. High scores indicate a better quality of life.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- participants aged between 45 to 80 years;
- participants diagnosed with mild to moderate hypertension, and meet the diagnostic criteria of mild to moderate hypertension according to 2018 Chinese guidelines for the management of hypertension (140≤SBP≤169 and/or 90≤DBP≤109);
- participants with or without antihypertensive medication;
- participants with no regular exercise in the past 3 months;
- participants willing to comply with the study protocol;
- participants willing to sign informed consent form.
Exclusion Criteria:
- participants diagnosed with secondary hypertension or refractory hypertension;
- participants with severe medical visceral condition and chronic diseases, such as diabetes, epilepsy, severe depression or anxiety, psychosis;
- participants with severe bone and joint diseases or motor dysfunction limit ability to participant exercise;
- participants with severe cognitive decline (Mini-Mental State Examination score, ≤ 20)
- participants with weak muscle, poor balance or limited vision that would impede full participation in the study;
- patients participate in other clinical trials at the same time.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04267471
Contact: Rongjiang Jin, PhD | 13808072058 | cdzyydxjrj@126.com | |
Contact: Juan Li, PhD | 785939016@qq.com |
China, Sichuan | |
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine (Sichuan Provincial Hospital of Traditional Chinese Medicine) | |
Chengdu, Sichuan, China, 610075 |
Study Chair: | Youping Liu, PhD | Chengdu University of Traditional Chinese Medicine |
Responsible Party: | Chengdu University of Traditional Chinese Medicine |
ClinicalTrials.gov Identifier: | NCT04267471 |
Other Study ID Numbers: |
2019KL-001 |
First Posted: | February 12, 2020 Key Record Dates |
Last Update Posted: | February 24, 2020 |
Last Verified: | February 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Tai Chi Hypertension Randomized Controlled Trial |
Hypertension Essential Hypertension Vascular Diseases Cardiovascular Diseases |